TA-7284-Low

DRUG2 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Type 2 Diabetes Mellitus

Phase 2

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

CompletedNCT01022112

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2009-11-30End: 2010-09-30Updated: 2026-01-08

Phase 3

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

CompletedNCT01387737

Tanabe Pharma CorporationType 2 Diabetes Mellitus

Start: 2011-05-31End: 2012-12-31Updated: 2026-01-08

Related Papers

Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.

2015-11-0321 citations

Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52‐week open‐label study

Journal of Diabetes Investigation2014-08-2568 citations